All articles by Jenna Philpott

Jenna Philpott

Jenna Philpott is a trainee healthcare and pharmaceutical reporter. Coming from a scientific background, Jenna has expertise in biochemistry, genetics and cancer science. Jenna previously wrote freelance articles focused on oncology and healthcare.

Insilico teams up with Menarini for breast cancer KAT6 inhibitor

Menarini’s subsidiary Stemline will receive upfront and milestone payments, with a potential value exceeding $500m, along with royalties from sales.

Tango Therapeutics doses first patient with USP1 inhibitor trial

Tango received US Food and Drug Administration (FDA) clearance on its investigational new drug application for TNG348 in September 2023.

Boehringer reinforces interest in NASH with new $2bn deal  

This collaboration comes six years after the German company Boehringer signed two agreements to develop treatments for NASH.

J&J seeks another FDA label for Rybrevant in NSCLC 

This signifies the third submission in four months from J&J for the Rybrevant development programme.

2023 in review: Cancer vaccines dose up on advances with tailored approaches 

As the number of patients with cancers continues to grow globally, research into personalised cancer vaccines is vital. 

Sudo raises $116m to advance TYK2 programmes 

Sudo plans to advance two tyrosine kinase 2 (TYK2) candidates into clinical testing next year for the treatment of autoimmune and neurologic conditions.

Bluebird seeks $250m raise as priority voucher gambit falls short  

Bluebird bio will secure up to $250m after a surprise decision from the US Food and Drug Administration (FDA) to hold back a priority review voucher.

POINT’s prostate cancer trial meets primary endpoint as Lilly’s offer looms 

The topline data announcement comes on the same day as Lilly further extends its tender offer for the acquisition of POINT.

Anagenex and Nimbus team up for small molecule drug discovery 

The companies will prioritise challenging drug targets across multiple therapy areas, leveraging Anagenex’s AI platform.

Illumina to divest Grail after two years of lawsuits 

Illumina aims to finalise the terms of this divestiture by the end of the second quarter of 2024.